Mobilization Factors of Peripheral Blood Stem Cells in Healthy Donors

Abstract

As a source of hematopoietic stem cells for transplantation, the use of peripheral blood stem cells (PBSCs) has become routine and comparable to that of the use of bone marrow. Recently, elderly patients with hematological malignancies also have been allowed to receive minitransplantations with nonmyeloablative conditioning regimens under sufficient PBSC infusion. As a result of these minitransplantations, elderly donors have been chosen increasingly from the siblings of elderly patients. We analyzed factors influencing the condition of CD34+ cells in the first days of collection in 49 healthy donors from July 1995 to January 2001. The median dose of recombinant human granulocyte colony-stimulating factor was 8 g/kg/day (range 8 ∼ 10) over 3 days. The target number of CD34+ cells used in this study was м 3 × 10 6 cells/kg of recipient body weight. The median apheresis volume was 12 L. Except for one 60 year old man, we obtained an adequate number of stem cells. In the regression analysis, a negative correlation was seen between donor age and the number of CD34+ cells/kg of recipient body weight per 12 L volume (Y ‫ס‬ aX + b; a ‫ס‬ −0.07507; b ‫ס‬ 6.629996; r ‫ס‬ −0.50985; p ‫ס‬ 0.000252). Significantly higher apheresis results were obtained in donors younger than 45 years compared with donors 45 years old and older (p < 0.0227). There were no correlations among the number of CD34+ cells, donor body weight, and the number of leukocytes in peripheral blood on the first day of apheresis. Key Words: CD34 positive cells-Donor age-Peripheral blood stem cell.Peripheral blood stem cells (PBSCs) mobilized by granulocyte colony-stimulating factor (G-CSF) and collected by apheresis are increasingly being used along with bone marrow for transplantation (1-3). With regard to the use of PBSCs for allogeneic hematopoietic stem cell transplantation, additional issues must be considered, such as the safety of healthy donors during apheresis. The second that must be considered is the most appropriate schedule for PBSC mobilization and harvesting. In addition, the number of elderly donors has recently increased due to the widespread use of minitransplantation (4,5). There are various reports suggesting that donor age affects the yield of PBSCs (6-10) while at the same time there are reports suggesting the opposite (11)(12)(13). It is necessary to plan transplantations and PBSC harvests adequately. In an attempt to better understand the factors influencing the mobilization and collection of CD34+ cells in healthy donors, we have analyzed the yields of CD34+ cells from 49 donors. MATERIALS AND METHODS Donor characteristics and apheresisA total of 49 consecutive healthy donors were included in this study (23 men, 26 women) from July 1995 to January 2001. Written informed consent was obtained from every donor before they underwent the procedure. The donors who had complications (e.g., hypertension and hyperlipidemia) were excluded. Apheresis was performed through peripheral venous access for all donors. The median age of the subjects w...

Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study

“…Of 56 donors, 30 were below 18 years, and therefore the impact of donor's age probably was not detectable in our cohort. Shimizu et al 28 described this phenomenon only in female donors.…”

The mobilization of CD34 positive mononuclear cells after myocardial infarction is abolished by revascularization of the culprit vessel

“…Although, there is evidence for a negative correlation between peripheral blood stem cell mobilization and age [13,14], so far, no other study has explored a correlation between the basic levels of CD34 positive cells and age. Here, we find a threefold difference in CD34 count between young healthy volunteers and older patients with angiographically unobstructed coronaries.…”

Peripheral blood stem cell mobilization from healthy donors

“…Due to effect of G-CSF is dosedependent, as a strategy for sufficient PBSC harvest, administration of the optimal dose of G-CSF, avoiding from the severe side-effects, is effective for the steady-state mobilization of PBSCs [3]. Kröger et al compared 10 μg/kg recombinant G-CSF (filgrastim) given as 5 μg/kg twice daily and 16 μg/kg, given as 8 μg/kg twice daily doses of G-CSF for stem cell mobilization in 90 healthy donors for ASCT in a retrospective analysis.…”

“…On the other hand the disadvantages of PBSC are exposure to hematopoietic growth factor and side-effects and possibility of more than one apheresis sessions needed. Younger donor age [3], lower donor body mass index, optimal G-CSF dose and administration schedule [4], higher white blood cell (WBC) count before mobilization, higher platelet count before and during the mobilization, and lower blood withdrawal rate during collection are the factors that significantly associated with a higher yield of PBSCs, and CD34+ cells in healthy donors [1,5].…”